{
    "clinical_study": {
        "@rank": "75486", 
        "arm_group": {
            "arm_group_label": "Closed-loop blood glucose control", 
            "arm_group_type": "Experimental", 
            "description": "Type 1 diabetes, Type 2 diabetes, total daily dose (TDD) of insulin that is > 1 u/kg or > 2 u/kg."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to test an experimental medical device designed to\n      automatically control blood sugar.  This device was designed for use by patients with\n      diabetes while they are in the hospital, and others who may develop high blood sugar as a\n      result of their medical problems."
        }, 
        "brief_title": "Inpatient Closed-loop Glucose Control", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes Mellitus", 
            "Hyperglycemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Hyperglycemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "The goal of this first-in-man trial is to test the safety and efficacy of the automated,\n      closed-loop control system in insulin sensitive subjects with type 1 diabetes, insulin\n      sensitive subjects with type 2 diabetes (TTD > 1u/kg/day), and subjects with type 2 diabetes\n      and substantial insulin resistance (<2 u/kg/day). The results of this study will help to\n      design future studies, exploring the use of the closed-loop system for BG control in\n      hospitalized patients, including those with diabetes or hyperglycemia of critical illness."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Subjects with type 1 diabetes\n\n          -  Age  21 to 75 with clinical type 1 diabetes for at least one year\n\n          -  Diabetes managed using an insulin infusion pump and rapid- or very-rapid-acting\n             insulins\n\n          -  Total daily dose (TDD) of insulin that is < 1 u/kg\n\n        Subjects with type 2 diabetes\n\n          -  Age  21 to 75 with clinical type 2 diabetes for at least one year\n\n          -  Diabetes managed using NPH as the basal insulin, which may be supplemented with\n             regular or rapid-acting insulin\n\n          -  Total daily dose (TDD) of insulin that is > 1 u/kg/day but < 2 u/kg/day or > 2\n             u/kg/day\n\n        Exclusion Criteria:\n\n          -  Pregnancy\n\n          -  Renal insufficiency\n\n          -  Cancer\n\n          -  Abnormal EKG suggestive of coronary artery disease or increased risk of malignant\n             arrhythmia\n\n          -  Acute illness or exacerbation of chronic illness at the time of the study procedure\n\n          -  Use of non-insulin, injectable anti-diabetic medications or oral anti-diabetic\n             medications other than metformin\n\n          -  History of allergy or adverse reaction to aspirin, peptic ulcers or bleeding\n             disorders\n\n          -  Known history of coronary artery disease, TIA or stroke\n\n          -  History of seizures\n\n          -  Transaminitis\n\n          -  Stage 2 hypertension at the time of screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01819844", 
            "org_study_id": "2011P000993"
        }, 
        "intervention": {
            "arm_group_label": "Closed-loop blood glucose control", 
            "description": "The InPatient Closed Loop Device is made up of the three components; the Abbott FreeStyle Navigator subcutaneous continuous glucose monitor, the Symbiq insulin-dextrose infusion system, and the control algorithm.  In this feasibility trial we will study 6 insulin-sensitive subjects with type 1 diabetes and 6 subjects with type 2 diabetes and a high insulin requirement (3 with total daily dose from 1-1.9 u/kg and 3 with total daily dose > 2 u/kg).", 
            "intervention_name": "Closed-loop blood glucose control", 
            "intervention_type": "Device", 
            "other_name": "InPatient Closed-Loop Blood Glucose Control Device."
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Closed-loop blood glucose control", 
            "Continuous glucose monitoring", 
            "Bionic pancreas", 
            "Artificial pancreas"
        ], 
        "lastchanged_date": "March 15, 2014", 
        "link": {
            "url": "http://www.bionicpancreas.org"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02114"
                }, 
                "name": "MGH Diabetes Research Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Subcutaneous Continuous Glucose Monitoring and Intravenous Dosing of Insulin and Dextrose for Automated Glycemic Control in the Inpatient Setting", 
        "overall_official": {
            "affiliation": "Massachusetts General Hospital", 
            "last_name": "Steven J Russell, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Average blood glucose over the closed-loop control period, as determined from GlucoScout measurements.", 
            "safety_issue": "No", 
            "time_frame": "12 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01819844"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Massachusetts General Hospital", 
            "investigator_full_name": "Steven J. Russell, MD, PhD", 
            "investigator_title": "Assistant Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of carbohydrate interventions (15 g) delivered according to study protocol", 
                "safety_issue": "Yes", 
                "time_frame": "12 hours"
            }, 
            {
                "measure": "Number of  BG events < 70 mg/dl  and nadir BG for each as determined form GlucoScout measurements", 
                "safety_issue": "Yes", 
                "time_frame": "12 hours"
            }, 
            {
                "measure": "Fraction of time spent within each of the following glucose ranges as determined from GlucoScout measurements: - < 70 mg/dl  - 70-120 mg/dl - 70-180 mg/dl  - >180 mg/dl", 
                "safety_issue": "Yes", 
                "time_frame": "12 hours"
            }, 
            {
                "measure": "Average blood glucose over the closed-loop control period as determined from the CGM driving the control algorithm", 
                "safety_issue": "Yes", 
                "time_frame": "12 hours"
            }, 
            {
                "measure": "Number of  BG events < 70 mg/dl  and nadir BG for each as determined from the CGM driving the control algorithm", 
                "safety_issue": "Yes", 
                "time_frame": "12 hours"
            }, 
            {
                "measure": "Fraction of time spent within each of the following glucose ranges as determined from the CGM driving the control algorithm: o < 70 mg/dl  o 70-120 mg/dl o 70-180 mg/dl  o >180 mg/dl", 
                "safety_issue": "No", 
                "time_frame": "12 hours"
            }, 
            {
                "measure": "Insulin dosing (u/kg)", 
                "safety_issue": "No", 
                "time_frame": "12 hours"
            }, 
            {
                "measure": "Dextrose dosing (g/kg)", 
                "safety_issue": "No", 
                "time_frame": "12 hours"
            }, 
            {
                "measure": "Plasma insulin levels", 
                "safety_issue": "No", 
                "time_frame": "12 hours"
            }, 
            {
                "measure": "Insulin clearance rate (t\u00bd)", 
                "safety_issue": "No", 
                "time_frame": "12 hours"
            }, 
            {
                "measure": "Accuracy of the CGM device using the GlucoScout measurements as the standard.", 
                "safety_issue": "Yes", 
                "time_frame": "12 hours"
            }
        ], 
        "source": "Massachusetts General Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Boston University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Massachusetts General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}